This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Child Development Disorders, Pervasive
Information about Child Development Disorders, Pervasive: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Child Development Disorders, Pervasive
Most recent studies have shown that Child Development Disorders, Pervasive shares some biological mechanisms with anxiety-disorders, asperger-syndrome, attention-deficit-hyperactivity-disorder, autism-spectrum-disorders, autistic-disorder, child-behavior-disorders, depressive-disorder, developmental-disabilities, epilepsy, impairment-(finding), language-development-disorders, language-disorders, malnutrition, mental-disorders, pervasive-development-disorder, psychotic-disorders, schizophrenia, stereotyped-behavior.
Among the many pathways, these few ones have gauged particular interests from scientists studying Child Development Disorders, Pervasive, and have been seen in publications frequently: Aging, Brain Development, Cell Activation, Cell Adhesion, Cognition, Excretion, Hypersensitivity, Localization, Locomotion, Methylation, Pathogenesis, Reflex, Secretion, Sensory Processing, Short-term Memory, Social Behavior, Synaptic Transmission, Translation, Visual Perception
Quite a number of genes have been found to play important roles in Child Development Disorders, Pervasive, such as ABCB6, AKR1C2, ARNTL, ARSD, ATP2A2, CNTNAP2, FANCA, FMR1, FXN, GNAI1, HTT, MECP2, NOS1, NOS2, PYCARD, SHANK2, SLC6A4, STS. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.